Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations
SAN DIEGO, Dec. 23, 2014 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enroll patients with NSCLC and another will enroll patients with other solid tumors. Both cohorts will enroll only those patients that have specific MET driver mutations including MET gene point mutations, gene amplification, and MET or Axl gene rearrangements.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.